Results 211 to 220 of about 28,421 (276)

Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review). [PDF]

Int J Mol Med
Xu J, Xia Z, Wang S, Xia Q.
europepmc   +1 more source

Correction: Experimental models for developing oncolytic virotherapy for metastatic prostate cancer. [PDF]

Front Immunol
Chen YC, Figueiredo ML.
europepmc   +1 more source

Future clinical potential of oncolytic virotherapy for pediatric CNS tumors [PDF]

, 2013
Cockle, JV, Melcher, A, Picton, SV
core   +1 more source

Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients [PDF]

, 2012
Sandeep Patil, Ivaylo Gentschev, Ingo Nölte, Gina Ogilvie, Aladar A. Szalay   +4 more
openalex   +1 more source

Experimental models for developing oncolytic virotherapy for metastatic prostate cancer. [PDF]

Front Immunol
Chen YC, Figueiredo ML.
europepmc   +1 more source

The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. [PDF]

Cells
Smestad J, Rieth J, Laux D, Milhem M.
europepmc   +1 more source

Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity. [PDF]

J Immunother Cancer
Hayes AJ, Davies EJ, Wilkinson M, Smith HG, Nenclares P, Lund T, Larkeryd A, Appleton E, Patin EC, Pedersen M, Rullan A, Mohamed HS, Aronson L, Murphy J, Grove L, Mansfield D, Mclaughlin M, Harrington KJ, Melcher A.   +18 more
europepmc   +1 more source

The Role of Natural Killer Cells in the Context of Oncolytic Herpes Simplex Virotherapy for Glioblastoma

, 2011
Christopher Alvarez‐Breckenridge
openalex   +1 more source

Editorial: Oncolytic virotherapy, volume II. [PDF]

Front Mol Biosci
Al-Shammari AM, Piccaluga PP.
europepmc   +1 more source

Durchbrechen von Therapieresistenzen [PDF]

, 2015

core   +1 more source